Apogee Therapeutics (APGE) | Financial Analysis & Statements
Apogee Therapeutics Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-78.1M
Net Income
-69.4M
Balance Sheet Metrics
Total Assets
937.1M
Total Liabilities
33.3M
Shareholders Equity
903.9M
Debt to Equity
0.04
Cash Flow Metrics
Operating Cash Flow
-56.2M
Free Cash Flow
-62.8M
Revenue & Profitability Trend
Apogee Therapeutics Income Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - |
| Gross Profit | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | ||||
| Research & Development | 214.7M | 167.9M | 68.4M | 27.8M |
| Selling, General & Administrative | 69.8M | 49.0M | 24.6M | 2.9M |
| Other Operating Expenses | - | - | - | - |
| Total Operating Expenses | 284.5M | 216.9M | 93.0M | 30.7M |
| Operating Income | -285.6M | -216.9M | -93.0M | -30.7M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | ||||
| Interest Income | 30.0M | 34.7M | 9.0M | 92.0K |
| Interest Expense | - | - | 0 | 9.2M |
| Other Non-Operating Income | - | - | - | - |
| Pre-tax Income | -255.6M | -182.1M | -84.0M | -39.8M |
| Income Tax | 278.0K | 18.0K | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -255.8M | -182.1M | -84.0M | -39.8M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | ||||
| EBITDA | -284.2M | -216.7M | -84.0M | -30.6M |
| EPS (Basic) | - | $-3.30 | $-3.36 | $-1.46 |
| EPS (Diluted) | - | $-3.30 | $-3.36 | $-1.46 |
| Basic Shares Outstanding | - | 55193971 | 25005774 | 27246823 |
| Diluted Shares Outstanding | - | 55193971 | 25005774 | 27246823 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Apogee Therapeutics Balance Sheet From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & Equivalents | 131.5M | 141.8M | 118.3M | 151.9M |
| Short-term Investments | 598.6M | 378.9M | 277.1M | 0 |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Other Current Assets | 605.0K | 1.7M | 1.2M | 57.0K |
| Total Current Assets | 741.4M | 529.7M | 398.4M | 152.1M |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 10.2M | 12.6M | 2.6M | - |
| Goodwill | - | - | - | - |
| Intangible Assets | - | - | - | - |
| Long-term Investments | - | - | - | - |
| Other Non-Current Assets | 8.7M | 498.0K | 401.0K | - |
| Total Non-Current Assets | 195.8M | 224.2M | 3.0M | 0 |
| Total Assets | 937.1M | 754.0M | 401.4M | 152.1M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | 1.2M | 1.1M | 2.1M | 418.0K |
| Short-term Debt | 3.5M | 3.2M | 1.1M | - |
| Current Portion of Long-term Debt | - | - | - | - |
| Other Current Liabilities | - | - | - | - |
| Total Current Liabilities | 27.9M | 28.6M | 20.6M | 10.0M |
| Non-Current Liabilities | ||||
| Long-term Debt | 5.3M | 8.6M | 933.0K | 0 |
| Deferred Tax Liabilities | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - |
| Total Non-Current Liabilities | 5.3M | 8.6M | 933.0K | 0 |
| Total Liabilities | 33.3M | 37.2M | 21.5M | 10.0M |
| Equity | ||||
| Common Stock | 1.0K | 1.0K | 0 | 0 |
| Retained Earnings | -561.8M | -305.9M | -123.8M | -39.8M |
| Treasury Stock | - | - | - | - |
| Other Equity | - | - | - | - |
| Total Shareholders Equity | 903.9M | 716.8M | 379.9M | 142.1M |
| Key Metrics | ||||
| Total Debt | 8.8M | 11.8M | 2.0M | 0 |
| Working Capital | 713.5M | 501.2M | 377.9M | 142.1M |
Balance Sheet Composition
Apogee Therapeutics Cash Flow Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -255.8M | -182.1M | -84.0M | -39.8M |
| Depreciation & Amortization | 1.4M | 189.0K | - | - |
| Stock-Based Compensation | 46.3M | 23.3M | 6.1M | 2.1M |
| Working Capital Changes | -12.3M | -2.2M | 1.2M | 418.0K |
| Operating Cash Flow | -216.8M | -159.1M | -76.6M | -25.8M |
| Investing Activities | ||||
| Capital Expenditures | -5.1M | -1.2M | -167.0K | 0 |
| Acquisitions | - | - | - | - |
| Investment Purchases | -642.3M | -649.4M | -303.7M | 0 |
| Investment Sales | 467.9M | 350.1M | 30.0M | 0 |
| Investing Cash Flow | -179.6M | -300.5M | -273.9M | 0 |
| Financing Activities | ||||
| Share Repurchases | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Debt Issuance | - | - | - | - |
| Debt Repayment | - | - | - | - |
| Financing Cash Flow | 389.6M | 493.5M | 315.4M | 168.3M |
| Free Cash Flow | -232.6M | -172.3M | -74.9M | -16.4M |
| Net Change in Cash | -6.7M | 33.9M | -35.1M | 142.5M |
Cash Flow Trend
Apogee Therapeutics Key Financial Ratios
Valuation Ratios
Forward P/E
-16.61
Price to Book
6.86
PEG Ratio
-16.61
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-31.57%
Return on Assets
-21.11%
Financial Health
Current Ratio
26.57
Debt to Equity
0.98
Beta
1.02
Per Share Data
EPS (TTM)
$-4.22
Book Value per Share
$13.21
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| APGE | 6.6B | - | 6.86 | -31.57% | 0.00% | 0.98 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






